AI Article Synopsis
- Glioma is a prevalent type of primary brain tumor, and high levels of CircRFX3 have been identified in this cancer, but its specific functions and mechanisms are not well understood.
- The study explored the role of CircRFX3 in glioma through various methods, including RNA and protein analysis, functional assays on glioma cells, and in vivo experiments to assess tumor growth.
- The findings showed that CircRFX3 is highly expressed in glioma cells, and its knockdown suppresses tumor growth, while overexpression does the opposite; it works by stabilizing RFX3 mRNA with the help of HNRNPK, which in turn promotes PROX1 transcription, further driving glioma progression.
Article Abstract
Background: Glioma is classified as one of the most common types of primary brain tumors. The high expression of CircRFX3 has been found in glioma. However, its functional roles in glioma and underlying mechanism remain unknown.
Purpose: Our study aimed to explore the function and specific mechanism of circRFX3 in glioma.
Methods: RT-qPCR or western blot was applied to examine the expression of RNAs or proteins. Functional assays were carried out to evaluate the influence of circRFX3, RFX3 and PROX1 on glioma cells. In vivo experiments were done to ascertain the impact of circRFX3 on glioma growth. Moreover, mechanism assays were conducted to investigate the molecular relation among circRFX3, RFX3, HNRNPK and PROX1.
Results: CircRFX3 was highly expressed in glioma cells. CircRFX3 knockdown led to the suppression of glioma cell and tumor growth. CircRFX3 overexpression resulted in the opposite outcomes. Mechanism analyses suggested that circRFX3 recruited HNRNPK to enhance RFX3 mRNA stability, thereby facilitating glioma cell malignant behaviors. RFX3 was also unveiled to affect glioma cells via stimulating PROX1 transcription.
Conclusion: CircRFX3, as a tumor promoter, could recruit HNRNPK to stabilize RFX3 mRNA in glioma cells. Additionally, RFX3 could promote PROX1 transcription to promote glioma progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12031-022-02005-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of Differentiation of 3T3-L1 Cells by Increasing Glioma-Associated Oncogene Expression in L. Using KCTC 3115.
Prev Nutr Food Sci
December 2024
Department of Culinary Arts & Hotel Food Service, Yeonsung University, Gyeonggi 14011, Korea.
The inhibitory effect of L. on adipocyte differentiation can be enhanced by lactic acid bacteria (LAB) fermentation. In this study, we assessed the cellulose resolution, L.
View Article and Find Full Text PDFSpatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis.
Front Immunol
December 2024
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.
Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.
Design and in silico analysis of a novel peptide-based multiepitope vaccine against glioblastoma multiforme by targeting tumor-associated macrophage.
Heliyon
December 2024
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
CD204 is a distinct indicator for tumor-associated macrophages (TAMs) in glioma. Evidence indicates that CD204-positive TAMs are involved in the aggressive behavior of various types of cancers. This study was conducted to develop a new and effective peptide-based vaccine for GBM, specifically targeting CD204.
View Article and Find Full Text PDFPreliminary evaluation of FAPI-04-PET/CT for differentiating recurrence and post-treatment changes in high-grade gliomas.
Explor Target Antitumor Ther
October 2024
Depts of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Dr E Borges Marg, Parel, Mumbai 400012, India.
Fibroblast-activated protein (FAP) expression in glial cells is attributed to FAP-positive foci on tumor vessels and neoplastic cells. Preclinical and pilot studies have shown FAP expression in high-grade gliomas. We aimed at comparing PET imaging with FAP-inhibitor (FAPI-PET) with current standard, i.
View Article and Find Full Text PDFChlorotoxin-functionalized mesoporous silica nanoparticles for pH-responsive paclitaxel delivery to Glioblastoma multiforme.
Heliyon
January 2025
BioSense Institute, University of Novi Sad, Dr Zorana Djindjica 1, 21000, Novi Sad, Serbia.
Glioblastoma multiforme (GBM) is a highly aggressive brain cancer associated with poor survival rates. We developed novel mesoporous silica nanoparticles (MSNs)-based nanocarriers for pH-responsive delivery of a therapeutic drug Paclitaxel (PTX) to GBM tumor cells. The pores of MSNs are loaded with PTX, which is retained by β-cyclodextrin (CD) moieties covalently linked to the pore entrances through a hydrazone linkage, which is cleavable in weakly acidic environment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!